Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.

While large pharmaceutical companies are filled with a wide breadth of smart people, smaller biotech firms offer a different kind of intellectual environment. They feature the same degree of brilliance, but it's concentrated in a much more focused organization, creating a unique depth of talent.

The transition from a leadership role at a large pharma company like Gilead to a biotech CEO involves a massive shift in scope. Instead of managing one large function with a large team, a biotech CEO is hands-on with every aspect of the company, from science to finance.

Voyager's CEO Al Sandrock left academia for biotech because he felt powerless treating ALS patients. He accepted the constraints of corporate strategy to be part of a team that could develop impactful drugs, a common trade-off for physician-scientists seeking greater patient impact.

Starting in business development at a large firm like Genentech provides a holistic understanding of the entire drug lifecycle—from discovery and regulation to clinical trials and marketing. This "full spectrum" view offers invaluable training for a future CEO.

Ron Cooper credits his success not to being a "scaling guy" at Bristol-Myers Squibb, but the "fix-it guy." Being deployed to turn around struggling business units across different geographies and therapeutic areas provided the multicultural, problem-solving toolkit essential for navigating the constant challenges of leading a biotech startup.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

A career on Wall Street can offer a unique advantage for biotech leadership. Unlike a pharma executive who might see only a few products through development, an analyst evaluates hundreds of companies. This builds an invaluable mental library of common failure modes and success patterns, enabling better strategic decisions.

Career advancement isn't always about deepening expertise in one narrow field. It can be driven by a curiosity to understand how different functions connect. This cross-functional perspective reveals process inefficiencies, and solving them leads to recognition, growth, and new opportunities.